Abstract Number: 1388 • 2019 ACR/ARP Annual Meeting
The Association Between Treatment of Abatacept or Other Target Disease-Modifying Anti-rheumatic Drugs and Type 2 Diabetes Mellitus (T2DM)-Related Healthcare Resource Utilization and Costs in Commercially Insured Rheumatoid Arthritis Patients with T2DM
Background/Purpose: Type 2 diabetes mellitus (T2DM)-related complications are costly, and there is lack of information regarding the comparative impact of target disease-modifying anti-rheumatic drugs (tDMARDs)…